Tags

Type your tag names separated by a space and hit enter

Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population.
J Am Coll Cardiol. 2007 Mar 20; 49(11):1193-202.JACC

Abstract

OBJECTIVES

This study was designed to determine whether alternate pro-B-type natriuretic peptide (proBNP) and BNP forms circulate in the general population.

BACKGROUND

Bioactive BNP(1-32) and NT-proBNP(1-76) are derived from a precursor molecule, proBNP(1-108). Recent data suggest that aminodipeptidase-processed forms of BNP(1-32) (BNP(3-32)) and of proBNP(1-108) itself (proBNP(3-108)) may circulate and have additional diagnostic potential.

METHODS

Residents (age > or =45 years) of Olmsted County, Minnesota, underwent medical review, echocardiography, and phlebotomy for 2 novel assays specific for proBNP(3-108) and BNP(3-32) and 2 commercial assays (Triage BNP and Roche NT-proBNP). Groups included normal subjects (n = 613), cardiovascular disease with normal ventricular function (n = 1,043), preclinical ventricular dysfunction (ALVD, n = 130), and chronic heart failure (HF, n = 52).

RESULTS

ProBNP(3-108) levels were above assay detection limits in 68% of normal subjects (50th; 25th to 75th percentiles: 7.85; 3.00 to 22.45 pmol/l) and correlated with age, gender, body size, and renal function and with results of commercial assays. ProBNP(3-108) levels were higher in ALVD (17.88; 6.07 to 42.76 pmol/l) or HF (42.75; 20.51 to 65.73 pmol/l), where they correlated more strongly with commercial assays. BNP(3-32) was above assay detection limits in 22% of normal subjects; levels were not correlated with age, body size, or renal function but were higher in HF. Neither novel assay was superior to commercial assays for the detection of ALVD or HF.

CONCLUSIONS

The presence of alternate circulating proBNP and BNP forms provides evidence for diverse proBNP and BNP processing in the general population. The physiologic consequences of these observations, both in terms of assay performance and endogenous BNP bioactivity, deserve further study.

Authors+Show Affiliations

Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17367664

Citation

Lam, Carolyn S P., et al. "Alternate Circulating pro-B-type Natriuretic Peptide and B-type Natriuretic Peptide Forms in the General Population." Journal of the American College of Cardiology, vol. 49, no. 11, 2007, pp. 1193-202.
Lam CS, Burnett JC, Costello-Boerrigter L, et al. Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. J Am Coll Cardiol. 2007;49(11):1193-202.
Lam, C. S., Burnett, J. C., Costello-Boerrigter, L., Rodeheffer, R. J., & Redfield, M. M. (2007). Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. Journal of the American College of Cardiology, 49(11), 1193-202.
Lam CS, et al. Alternate Circulating pro-B-type Natriuretic Peptide and B-type Natriuretic Peptide Forms in the General Population. J Am Coll Cardiol. 2007 Mar 20;49(11):1193-202. PubMed PMID: 17367664.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. AU - Lam,Carolyn S P, AU - Burnett,John C,Jr AU - Costello-Boerrigter,Lisa, AU - Rodeheffer,Richard J, AU - Redfield,Margaret M, Y1 - 2007/03/06/ PY - 2006/07/10/received PY - 2006/10/31/revised PY - 2006/11/02/accepted PY - 2007/3/21/pubmed PY - 2007/4/14/medline PY - 2007/3/21/entrez SP - 1193 EP - 202 JF - Journal of the American College of Cardiology JO - J Am Coll Cardiol VL - 49 IS - 11 N2 - OBJECTIVES: This study was designed to determine whether alternate pro-B-type natriuretic peptide (proBNP) and BNP forms circulate in the general population. BACKGROUND: Bioactive BNP(1-32) and NT-proBNP(1-76) are derived from a precursor molecule, proBNP(1-108). Recent data suggest that aminodipeptidase-processed forms of BNP(1-32) (BNP(3-32)) and of proBNP(1-108) itself (proBNP(3-108)) may circulate and have additional diagnostic potential. METHODS: Residents (age > or =45 years) of Olmsted County, Minnesota, underwent medical review, echocardiography, and phlebotomy for 2 novel assays specific for proBNP(3-108) and BNP(3-32) and 2 commercial assays (Triage BNP and Roche NT-proBNP). Groups included normal subjects (n = 613), cardiovascular disease with normal ventricular function (n = 1,043), preclinical ventricular dysfunction (ALVD, n = 130), and chronic heart failure (HF, n = 52). RESULTS: ProBNP(3-108) levels were above assay detection limits in 68% of normal subjects (50th; 25th to 75th percentiles: 7.85; 3.00 to 22.45 pmol/l) and correlated with age, gender, body size, and renal function and with results of commercial assays. ProBNP(3-108) levels were higher in ALVD (17.88; 6.07 to 42.76 pmol/l) or HF (42.75; 20.51 to 65.73 pmol/l), where they correlated more strongly with commercial assays. BNP(3-32) was above assay detection limits in 22% of normal subjects; levels were not correlated with age, body size, or renal function but were higher in HF. Neither novel assay was superior to commercial assays for the detection of ALVD or HF. CONCLUSIONS: The presence of alternate circulating proBNP and BNP forms provides evidence for diverse proBNP and BNP processing in the general population. The physiologic consequences of these observations, both in terms of assay performance and endogenous BNP bioactivity, deserve further study. SN - 1558-3597 UR - https://www.unboundmedicine.com/medline/citation/17367664/Alternate_circulating_pro_B_type_natriuretic_peptide_and_B_type_natriuretic_peptide_forms_in_the_general_population_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0735-1097(06)03205-0 DB - PRIME DP - Unbound Medicine ER -